fusion
viral
target
cell
membran
obligatori
step
infect
envelop
virus
develop
compound
peptid
particular
block
process
wellestablish
therapeut
strategi
clinic
valid
retroviru
human
immunodefici
viru
type
develop
peptid
fusion
inhibitor
enfuvirtid
also
known
viral
fusion
driven
special
protein
although
specif
viru
act
common
mechan
particular
preval
class
fusion
protein
harbor
two
heptad
repeat
hr
region
central
process
first
one
ntermin
region
adjac
fusion
peptid
hrn
second
one
ctermin
region
immedi
preced
transmembran
domain
hrc
current
accept
model
stipul
fusion
initi
bind
envelop
glycoprotein
gp
cellular
receptor
hrn
hrc
region
becom
separ
socal
prehairpin
intermedi
bridg
viral
cell
membran
prehairpin
structur
hrn
form
trimer
coiledcoil
fold
hrc
onto
hrn
trimer
lead
format
bundl
process
two
membran
driven
close
apposit
ultim
result
fusion
review
view
inhibitor
bind
prehairpin
intermedi
prevent
transit
inhibit
viral
entri
case
enfuvirtid
span
part
hrc
region
fusogen
protein
mechan
inhibit
appli
peptid
deriv
hr
region
mani
virus
characterist
sequenc
pattern
heptad
repeat
drive
format
coil
coil
provid
import
advantag
develop
peptidebas
antivir
put
hrn
hrc
peptid
viral
fusion
protein
easili
identifi
directli
genom
inform
comput
program
like
learncoil
multicoil
inde
emerg
coronaviru
recent
year
caus
sar
outbreak
identif
hrn
hrc
region
develop
peptid
inhibitor
preced
determin
structur
fusion
protein
therefor
addit
viabl
strategi
known
virus
inhibit
viral
fusion
offer
opportun
rapid
respons
emerg
viral
pathogen
open
possibl
develop
specif
antivir
short
timefram
howev
potenc
hrderiv
peptid
differ
consider
among
envelop
virus
hiv
particularli
favor
case
reason
differ
fulli
establish
although
major
factor
repres
fusion
kinet
inde
virus
slower
transit
hairpin
intermedi
offer
longer
window
opportun
peptid
inhibitor
accordingli
show
greater
potenc
sever
peptid
engin
strategi
success
appli
increas
potenc
peptid
fusion
inhibitor
howev
requir
sequencespecif
modif
rel
timeconsum
optim
process
taken
differ
approach
seek
way
increas
antivir
activ
without
need
chang
nativ
hrderiv
sequenc
end
previous
report
attach
cholesterol
group
peptid
fusion
inhibitor
cholesteroltag
dramat
increas
antivir
potenc
cholesteroltag
peptid
hrc
domain
produc
inhibitor
depend
viral
strain
test
potent
unconjug
potent
clinic
drug
enfuvirtid
show
result
select
enrich
peptid
membran
viral
fusion
occur
cholesteroltag
therefor
appear
gener
method
applic
mani
envelop
virus
recent
shown
cholesterol
tag
hrc
peptid
paramyxoviru
human
parainfluenza
viru
type
also
increas
antivir
potenc
notabl
peptid
maintain
abil
unconjug
peptid
inhibit
emerg
paramyxovirus
hendra
viru
hev
nipah
viru
niv
fatal
human
cholesteroltag
peptid
acquir
abil
also
inhibit
rubulaviru
also
known
nipah
viru
cholesteroltag
hrc
peptid
activ
vivo
effect
prevent
treat
establish
anim
model
would
otherwis
fatal
nipah
viru
enceph
addit
advantag
cholesterol
tag
prolong
halflif
peptid
vivo
bind
serum
protein
pharmacokinet
pk
studi
mice
concentr
mgkg
show
wherea
unconjug
undetect
plasma
h
nm
still
detect
h
inject
concentr
higher
measur
multipl
strain
expand
gener
method
potenti
activ
natur
hrc
peptid
inhibitor
assess
valu
dimer
fusion
inhibitor
sever
exampl
success
use
multimer
increas
potenc
fusion
inhibitor
entri
inhibitor
report
hypothes
avid
effect
dimerizationmultimer
work
reduc
koff
inhibitorfus
protein
complex
format
cholesterol
tag
hand
facilit
encount
peptid
viral
target
protein
enrich
peptid
target
membran
effect
increas
kon
complex
format
two
modif
could
therefor
work
concert
implement
without
requir
optim
nativ
sequenc
hrnhrc
peptid
follow
report
design
cholesteroltag
dimer
fusion
inhibitor
demonstr
efficaci
prevent
curtail
niv
replic
vitro
vivo
design
moieti
contain
cholesterol
group
branch
function
incorpor
featur
list
firstli
includ
singl
cholesterol
group
one
hand
given
consider
reduct
solubl
cholesterol
moieti
want
avoid
multipl
copi
hand
hypothes
balanc
cholesterol
polypeptid
moieti
would
still
provid
effici
anchor
multimer
inhibitor
membran
raft
singl
anchor
moieti
suffici
protein
consider
larger
size
even
larg
copi
number
multimer
inhibitor
monom
size
amino
acid
data
publish
work
complet
lend
support
hypothesi
moreov
envisag
two
copi
inhibitor
sequenc
discuss
secondli
decid
focu
dimer
inhibitor
find
kay
cowork
suggest
despit
trimer
structur
fusion
intermedi
maximum
benefit
multimer
achiev
level
dimer
littl
even
addit
benefit
trimer
inhibitor
thirdli
select
four
polyethylen
glycol
peg
unit
spacer
monom
cholesterol
core
figur
would
provid
approxim
distanc
monom
success
use
welch
et
al
moreov
found
spacer
peptid
cholesterol
benefici
monomer
fusion
inhibitor
notabl
subsequ
public
welch
et
al
show
reduct
linker
length
provid
consider
increas
potenc
clearli
area
requir
explor
nextgener
branch
core
fourthli
select
maleimid
wellestablish
chemoselect
reactiv
moieti
conjug
cholesterolcontain
core
cysteinecontain
peptid
structur
cholesterolcontain
dimer
core
shown
figur
compound
stabl
store
use
reliabl
least
month
peptid
use
studi
list
tabl
dimer
cholesteroltag
fusion
inhibitor
prepar
via
conjug
cysteinecontain
peptid
precursor
maleimidefunction
core
initi
consid
bromoacetyl
group
reactiv
moieti
done
monomer
cholesteroltag
inhibitor
correspond
function
core
prepar
describ
see
figur
use
last
step
bromoacetyl
anhydrid
instead
acid
howev
turn
difficult
control
competit
reactiv
core
peptid
hydrolysi
bromoacetyl
group
lead
difficulttosepar
mixtur
dimer
momomericcap
conjug
use
maleimid
instead
reactiv
moieti
reaction
straightforward
proceed
rapidli
good
overal
yield
initi
focus
niv
virus
repres
major
unmet
medic
need
previou
find
hrc
peptid
deriv
sequenc
effect
niv
rais
possibl
develop
singl
inhibitor
moreov
cholesteroltag
peptid
consider
improv
antivir
potenc
virus
howev
cholesteroltag
inhibitor
yet
potent
enough
sinc
requir
sequenc
optim
display
activ
vivo
sequenc
therefor
offer
ideal
opportun
test
dimer
coupl
cholesteroltag
could
provid
potenc
enhanc
comparison
cholesteroltag
alon
recent
shown
peptid
efficaci
vivo
directli
correl
inhibit
viral
fusion
celltocel
spread
peptid
inhibitor
abl
inhibit
viral
entri
ineffici
block
celltocel
fusion
effect
natur
host
base
data
decid
use
celltocel
fusion
assay
use
cell
coexpress
envelop
viral
glycoprotein
figur
niv
figur
stringent
vitro
assay
evalu
peptid
efficaci
figur
show
comparison
fusion
inhibitori
activ
cholesteroltag
monom
cholesteroltag
dimer
deriv
peptid
sequenc
comparison
also
show
fusion
inhibitori
activ
nativ
untag
peptid
inhibitor
control
peptid
dimer
via
linker
similar
one
use
welch
et
al
cholesteroltag
dimer
consider
potent
cholesteroltag
monom
turn
potent
untag
inhibitor
notabl
case
advantag
observ
dimer
alon
exert
posit
effect
presenc
cholesterol
moieti
encourag
data
test
cholesteroltag
dimer
niv
hrc
peptid
activ
viru
figur
show
comparison
fusion
inhibitori
activ
niv
fusion
monomer
fusion
inhibitor
monomer
cholesteroltag
inhibitor
dimer
inhibitor
dimer
cholesteroltag
inhibitor
also
case
dimericcholesterol
tag
inhibitor
potent
cholesteroltag
monom
untag
monom
untag
dimer
show
similar
lower
potenc
experi
progress
nativ
hrc
sequenc
potent
inhibitor
without
need
extens
sequenc
optim
rel
weak
fusion
inhibitor
nm
turn
reason
potent
peptid
nm
nm
niv
potent
inhibitor
nm
nm
niv
confirm
vitro
efficaci
use
niv
live
viru
plaqu
reduct
assay
found
valu
nm
cholesterol
tag
monom
nm
cholesterol
tag
dimer
previous
shown
cholesterol
tag
peptid
highli
effect
block
viral
entri
increas
potenc
due
dimer
could
appreci
celltocel
fusion
assay
figur
turn
attent
regard
face
opposit
end
spectrum
term
potenc
enhanc
sinc
nativ
hrc
peptid
alreadi
potent
fusion
inhibitor
potenc
cholesteroltag
peptid
picomolar
rang
moreov
access
prehairpin
intermedi
appear
steric
restrict
limit
access
larg
protein
would
elimin
potenti
benefici
effect
multimer
compar
inhibitori
activ
infect
untag
fusion
inhibitor
monomer
cholesteroltag
inhibitor
dimer
cholesteroltag
inhibitor
correspond
dimer
without
cholesterol
tag
two
strain
use
coreceptortrop
strain
bal
coreptortrop
strain
laiiiib
shown
figur
cholesteroltag
dimer
extrem
potent
inhibitor
iiib
bal
strain
pm
pm
respect
potenc
increas
versu
untag
hrderiv
peptid
two
strain
nm
nm
iiib
bal
monomer
cholesteroltag
inhibitor
compar
potent
pm
pm
iiib
bal
compar
potenc
cholesteroltag
monom
dimer
suggest
reach
previous
identifi
potenc
plateau
highaffin
inhibitor
increas
stabil
form
peptid
translat
higher
antivir
potenc
kay
cowork
shown
inhibitor
reach
beyond
threshold
extraaffin
repres
resist
capacitor
ie
reserv
bind
energi
counteract
onset
resist
due
affinitydisrupt
mutat
current
investig
whether
case
cholesteroltag
hiv
dimer
inhibitor
base
data
select
hpivniv
inhibitor
vivo
test
previous
shown
golden
hamster
suitabl
small
anim
model
niv
infect
sinc
develop
cn
manifest
diseas
similar
human
diseas
unlik
cat
ferret
develop
primarili
respiratori
diseas
efficaci
investig
administ
peptid
golden
hamster
intraperiton
concurr
viru
infect
dose
mgkg
inject
peptid
repeat
everi
day
day
postinfect
hamster
infect
intraperiton
inocul
niv
use
infect
hamster
observ
daili
clinic
sign
prostrat
neurolog
sign
variat
temperatur
weight
untreat
anim
euthan
within
day
infect
due
neurolog
diseas
figur
treatment
peptid
result
surviv
one
five
anim
onset
ill
consider
delay
four
lead
significantli
extend
lifespan
figur
vivo
activ
provid
proof
concept
antivir
efficaci
dimer
cholesteroltag
peptid
inject
peptid
absenc
viru
challeng
result
appar
toxic
anim
mockinfect
group
healthi
end
observ
period
figur
conclus
shown
dimer
hrcderiv
fusion
inhibitori
peptid
conjunct
cholesterol
tag
may
gener
strategi
increas
antivir
potenc
vitro
dimer
effect
vivo
observ
complement
previou
report
cholesteroltag
fusion
inhibitor
envisag
sever
area
improv
current
inhibitor
seri
optim
length
linker
join
monom
may
provid
consider
increas
potenc
specif
demonstr
hiv
work
kay
cowork
use
synthet
scheme
shown
figur
maleimidefunction
core
peg
spacer
differ
length
easili
prepar
react
precursor
rapidli
select
potent
inhibitor
also
although
focus
dimer
peptid
trimer
higher
copi
number
core
may
provid
advantag
especi
start
hrc
inhibitor
weak
final
chemoselect
pair
may
prove
superior
term
reactiv
yield
maleimidecystein
pair
note
howev
latter
pair
offer
safeti
advantag
sinc
featur
antibodydrug
conjug
recent
approv
human
use
seattl
genet
stage
cholesteroltag
dimer
repres
feasibl
strategi
boost
inhibitori
potenc
level
case
may
compat
vivo
use
without
need
extens
sequenc
optim
avail
necessari
build
block
synthesi
cholesteroltag
monom
dimer
easili
rapidli
accomplish
precursor
peptid
strategi
may
contribut
emerg
respons
outbreak
exist
novel
virus
activ
vivo
dimer
cholesteroltag
inhibitor
niv
support
potenti
util
strategi
current
explor
scope
approach
sever
envelop
virus
synthesi
cholesterolcontain
branch
core
detail
figur
synthesi
peptid
tabl
alreadi
describ
chemoselect
conjug
cyspeptid
precursor
cholesterol
deriv
yield
conjug
tabl
detail
figur
nipah
viru
isol
genbank
prepar
cell
describ
previous
biosafeti
level
laboratori
jean
merieux
lyon
franc
plaqu
reduct
assay
serial
dilut
peptid
dulbecco
modifi
eagl
medium
dmem
invitrogen
ad
report
cell
monolay
vero
cell
cellswel
pfu
niv
ad
supernat
vero
cell
incub
supernat
replac
carboxymethylcellulos
dmem
contain
fc
plate
incub
day
plate
final
reveal
classic
central
plaqu
assay
previous
describ
guillaum
et
al
ref
calcul
use
graph
pad
softwar
data
express
deviat
sd
tzmbl
cell
line
epitheli
heladeriv
cell
line
engin
express
integr
report
gene
firefli
luciferas
luc
ecoli
control
ltr
transactiv
tat
protein
synthes
infect
cell
seed
flat
bottom
plastic
plate
falcon
becton
dickinson
labwar
lincoln
park
nj
cellswel
incub
presenc
absenc
compound
h
total
volum
aliquot
viral
stock
multipl
infect
moi
ad
total
volum
cultur
medium
contain
deaedextran
sigmaaldrich
st
loui
mo
fortyeight
h
later
effici
viru
infect
determin
rel
luc
unit
rlu
luciferas
assay
system
promega
madison
wi
pbmc
isol
blood
obtain
new
york
blood
center
cultur
rpmi
supplement
fb
mm
lglutamin
cellgro
uml
arrrp
contribut
hoffmanlaroch
inc
cultur
medium
half
pbmc
cultur
stimul
phytohemagglutinin
pha
sigma
st
loui
mo
half
mab
supernat
hybridoma
cultur
medium
directli
isol
day
differ
stimul
cell
mix
equal
proport
wash
suspend
cultur
medium
supplement
penicillinstreptomycin
remaind
cultur
pbmc
seed
cellsml
per
well
plate
addit
serial
dilut
inhibitor
immedi
prior
inocul
test
viru
replic
measur
use
inhous
gag
antigen
elisa
day
cultur
residu
gag
input
viru
replic
per
assay
measur
subtract
net
gag
product
test
well
compar
control
well
inhibitor
replicatesassay
defin
inhibitor
titrat
step
cultur
well
mix
cell
supernat
analyz
two
assay
replic
per
condit
combin
elisa
eg
assay
viral
growth
control
well
see
combin
elisa
well
adapt
assay
detect
earli
stage
fusion
activ
sinc
readout
depend
upon
downstream
transactiv
event
use
assay
experi
greater
rang
detect
assay
necessari
assay
base
alpha
complement
betag
betag
protein
lack
ntermin
residu
omega
peptid
express
one
plasmid
ntermin
residu
alpha
peptid
express
second
plasmid
cell
fusion
lead
complement
betagalactosidas
quantit
use
galactostar
appli
biosystem
chemiluminesc
report
gene
assay
system
receptor
bear
cell
express
omega
peptid
mix
viral
glycoprotein
coexpress
cell
also
express
alpha
peptid
variou
temperatur
specif
time
point
fusion
stop
lyse
cell
lysi
buffer
fusion
inhibitori
peptid
ad
two
set
cell
mix
togeth
eightweekold
golden
hamster
mesocricetu
auratu
janvier
franc
anesthet
infect
intraperiton
ip
ml
niv
laboratori
group
anim
treat
daili
ip
inject
peptid
mgkg
day
start
day
infect
left
untreat
anim
follow
daili
week
comparison
surviv
curv
analysi
perform
use
test
use
graph
pad
program
anim
handl
strict
accord
good
anim
practic
defin
french
nation
charter
ethic
anim
experiment
effort
made
minim
suffer
anim
work
approv
region
ethic
committe
ethiqu
pour
l
experiment
anim
ceccapp
protocol
experi
perform
inserm
jean
laboratori
lyon
franc
french
anim
regul
committe
